SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q1 2025 vs. Q4 2024
How the institutions holding SAB Biotherapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 25 | 26 | +1 |
| Shares | 2.63M | 2.21M | −423.5K (−16.1%) |
| Value | $10.1M | $2.99M | −$7.12M (−70.4%) |
New holders (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Silver Oak Securities, Inc | 20,188 | $29.9K | 0.00% |
| XTX Topco Ltd | 16,555 | $22.3K | 0.00% |
| Renaissance Technologies LLC | 10,030 | $13.6K | 0.00% |
| SBI Securities Co., Ltd. | 50 | $68 | 0.00% |
Sold out (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Marshall Wace, LLP | 459,168 | $1.75M |
| Diadema Partners LP | 30,000 | $113.8K |
| Federation des caisses Desjardins du Quebec | 250 | $949 |